Qiu YX, Jian KY, Xu QR, Lu X, Jia BL, Jiang L, Liang F. OncoVee™-mini-patient-derived xenograft guided adjuvant chemotherapy treatment for resectable gastric cancer. World J Gastrointest Oncol 2026; 18(7): 118050 [DOI: 10.4251/wjgo.v18.i7.118050]
Corresponding Author of This Article
Feng Liang, PhD, Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. lfpeakcool@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
research-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Yu-Xuan Qiu, Feng Liang, Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
Kai-Yu Jian, Qian-Ru Xu, Xin Lu, Bao-Lei Jia, Lin Jiang, Department of General Surgery, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100853, China
Co-first authors: Yu-Xuan Qiu and Kai-Yu Jian.
Author contributions: Qiu YX and Jian KY drafted the manuscript, collected clinical data, and performed the statistical analyses, contributed equally to this work as co-first authors; Liang F conceptualized and designed the study; Xu QR and Lu X assisted with data curation and patient follow-up assessments; Jia BL and Jiang L contributed to the methodology, specifically regarding the mini patient-derived xenograft testing procedures and imaging evaluations; Liang F critically revised the manuscript for important intellectual content and supervised the project. All authors read and approved the final manuscript.
Institutional review board statement: The study protocol was reviewed and approved by the Ethics Committee of Tongxin County People’s Hospital of Ningxia, No. 001.
Informed consent statement: All patients signed a written informed consent form prior to their inclusion.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Corresponding author: Feng Liang, PhD, Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. lfpeakcool@126.com
Received: January 27, 2026 Revised: February 21, 2026 Accepted: April 8, 2026 Published online: July 15, 2026 Processing time: 160 Days and 9.9 Hours
Abstract
BACKGROUND
Most patients with resectable gastric cancer require postoperative adjuvant chemotherapy, and appropriate drug or regimen selection is crucial for improving their prognosis. The clinical application in antitumor drug sensitivity testing for gastric cancer is challenging owing to low success rates and prolonged establishment times involving gastric cancer patient-derived xenograft models.
AIM
To determine whether OncoVee™-mini patient-derived xenograft (MiniPDX)-guided adjuvant chemotherapy improves outcomes for patients with resectable gastric cancer compared with conventional guideline-based chemotherapy.
METHODS
This retrospective study, comprising 36 enrolled patients with resectable gastric cancer, divided patients into a MiniPDX group (OncoVee™-MiniPDX model used to screen for the most sensitive drug or regimen and to guide clinical treatment) or an experiential treatment group (patients received conventional drug treatment according to clinical guidelines, without MiniPDX-based drug sensitivity screening), based on their preferences. The primary endpoint was recurrence-free survival (RFS); secondary endpoints were overall survival (OS).
RESULTS
Baseline characteristics in the MiniPDX and experimental treatment groups (16 and 20 patients, respectively) were balanced. The mean RFS was 48.2 [95% confidence interval (CI): 37.9-58.5] and 32.7 (95%CI: 23.7-41.7) months, respectively. Drug susceptibility testing using the MiniPDX model significantly improved patients’ RFS (mean: 48.2 months vs 32.7 months, respectively; P = 0.025). The mean OS was 54.5 (95%CI: 46.9-62.1) and 43.5 (95%CI: 36.2-50.7) months, respectively, indicating a significant OS benefit with MiniPDX-guided therapy (mean: 54.5 months vs 43.5 months, respectively; P = 0.036). Multivariate Cox analysis indicated that MiniPDX testing (adjusted hazard ratio = 0.266, 95%CI: 0.087-0.816, P = 0.021) was a protective factor for RFS and for OS (adjusted hazard ratio = 0.83, 95%CI: 0.081-0.997, P = 0.050). Log-rank and multivariate Cox analyses demonstrated superior RFS and OS in the Mini-PDX group.
CONCLUSION
The Oncovee™-MiniPDX model can be used to detect drug sensitivity in postoperative adjuvant therapy for gastric cancer and improve the RFS and OS for patients with resectable gastric cancer. Further studies are needed to validate our findings.
Core Tip: In this retrospective study, OncoVee™-mini patient-derived xenograft-guided postoperative adjuvant chemotherapy significantly improved recurrence-free survival and overall survival in patients with resectable gastric cancer compared with conventional experience-based treatment. The mini patient-derived xenograft platform enables rapid in vivo drug sensitivity testing within 7 days and may provide a feasible strategy for individualized precision chemotherapy selection in clinical practice.
